Multicenter phase II study of capecitabine plus cisplatin as first-line therapy for human epidermal growth factor receptor 2-negative advanced gastric cancer: Yokohama Clinical Oncology Group Study YCOG1107
Crossref DOI link: https://doi.org/10.1007/s00280-017-3430-6
Published Online: 2017-09-14
Published Print: 2017-11
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Sato, Kei
Kunisaki, Chikara
Kosaka, Takashi
Takagawa, Ryo
Takahashi, Masazumi
Izumisawa, Yusuke
Miyamoto, Hiroshi
Sato, Sho
Tanaka, Yusaku
Yamaguchi, Naotaka
Kimura, Jun
Ono, Hidetaka A.
Makino, Hirochika
Akiyama, Hirotoshi
Endo, Itaru
License valid from 2017-09-14